How Parimer is Helping in Early Detection of Parkinson’s Disease
.png)
Nicole K, Polinski, PhD, director of research resources at The Michael J. Fox Foundation, worked with Parimer to develop an important reagent required for the development of novel imaging tracers for neurodegenerative diseases diagnosis and monitoring. They plan to expand its availability with the help of Parimer.
How Parimer and The Michael J. Fox Foundation Worked Together
Development of the Imaging Tracer
Parimer collaborated with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop a critical reagent required for the evaluation of novel imaging tracers for early Parkinson’s disease detection.
The product uses a gel to test imaging binders for Parkinson's by identifying specific disease markers in biological samples.
Parimer produced small batches in partnership with third-party Parkinson’s disease imaging experts, focusing on optimizing the formulation while addressing challenges like production cost and scalability for wider research accessibility.
Challenges in Manufacturing and Scaling
This evaluation of novel imaging tracers is dependent on a key component made in a bygone era. This critical component was once made by half a dozen manufacturers around the world; however, they have slowly closed operations and ceased production.
This left imaging development researchers without a source of a critical component as all the prior manufacturers declined to support small batch manufacturing of this product again. Researchers raised these issues with MJFF, leading to a partnership between MJFF and Parimer to fill this crucial gap.
Parimer is reverse engineering the discontinued products from competitors and resume manufacturing in a controlled environment suitable for medical applications.
Project Plan
MJFF provided Parimer with a grant at the start of Q4 2024. By the start of Q1 2025, a promising prototype is already in hand with hopes the final product will be ready by the end of Q1 2025.
Both parties are looking to expand the product's availability for wider use in the research community and provide this critical reagent to any researcher seeking to evaluate novel imaging tracers for human disease, focusing on long-term sustainability, predicting production needs, and addressing challenges like shelf life.

Results and Impact
Parimer supported The Michael J. Fox Foundation to develop a product crucial for the development of imaging markers for Parkinson’s disease.
Parimer has helped the Foundation by advising on balancing production costs and creating accessibility to the research community.